This presentation is intended to present a summary of ACT’s (“ACT”, or “Advanced Cell

Technology Inc”, or “the Company”) salient business characteristics.

The information herein contains “forward-looking statements” as defined under the

federal securities laws. Actual results could vary materially. Factors that could cause

actual results to vary materially are described in our filings with the Securities and

Exchange Commission.

You should pay particular attention to the “risk factors” contained in documents we file

from time to time with the Securities and Exchange Commission. The risks identified

therein, as well as others not identified by the Company, could cause the Company’s

actual results to differ materially from those expressed in any forward-looking

statements. Ropes Gray

Cautionary Statement Concerning Forward-Looking Statements

1

LEADING

REGENERATIVE

MEDICINE

0

50

100

150

200

250 P

er

10

00

po

pu

latio

n

Arthritis/ other musculoskeletal

Heart/ other circulatory Vision

Exemplary Chronic Health Conditions Source: U.S. Census Bureau Publication “65+ in the United States”, P23-209

2

18-44

45-64

65-74

75+

Age

Groups

133.7 142.2 173.4 202.7 207.4 205.5

37.4 52.9

64.8

81.9 105.3 121

214.6 274.6

395.9

568.5

752.2

870.4

34.4

53.2

80.1

121

198.5

305.3

2010 2020 2030 2040 2050 2000 2010 2020 2030 2040 2050 2000

80 and over

65 to 79

Population Aged 65 and Older for Developed and

Developing Countries (in millions)

Developed Countries Developing Countries

Source: U.S. Census Bureau Publication “65+ in the United States”, P23-209

3

4

Structure of Retina

The Retina the light-sensitive

tissue lining the inner surface of

the eye

Retina

5

Life Support to Photoreceptors

Provides nutrients and growth factors

• photoreceptors see no blood

Recycles Vitamin A

• maintains photoreceptor excitability

Detoxifies photoreceptor layer

Maintains Bruch’s Membrane

• natural antiangiogenic barrier

• immune privilege of retina

Absorbs stray light / protects from UV

RPE Layer has

multiple critical roles

in the

health and function

of photoreceptors and the retina as a whole.

6

Life Support to Photoreceptors

Failure of RPE cells results in many degenerative diseases

Stargardt’s disease

Myopic Macular Dystrophy

Age-related macular degeneration (AMD)

7

RPE Therapy- Rationale

• Massive unmet medical need

• Easy to identify – aids manufacturing

• Small dosage size – less than 200K cells

• Immune-privileged site - minimal immunosuppression

• Ease of administration - no separate device approval

• Unique measuring and observation environment

Preclinical Models

8

Injected human RPE cells

repair monolayer

structure in eye

Transplanted cells

engraft and form

correct anatomical structure

Mouse model for macular degeneration

Preclinical Models

9

untreated treated

Photoreceptor

layer photoreceptor

layer is lost

Transplanted RPE cells

protect photoreceptors and

prevent loss of vision

Rat model for

macular degeneration

•Untreated animals go blind

• Treated animals maintain

70-80% of normal vision

10

Participation by the leading

retinal surgeons in the world

Jules Stein

(UCLA)

Mass

Eye & Ear

Infirmary

Wills Eye

Institute

Bascom

Palmer Eye

Institute

Moorfields

Eye

Hospital

Edinburgh

Royal

Infirmary

Surgical Overview

11

Procedure:

• 25 Gauge Pars Plana Vitrectomy

• Posterior Vitreous Separation

• Subretinal hESC-derived RPE cells

injection

• Bleb Confirmation

• Day Surgery/Sedation

Preliminary Results

12

No Adverse Events

No signs of hyperproliferation,

abnormal growth, rejection or retinal

detachment.

Persistence of cells

Anatomical evidence of hESC-RPE

survival and engraftment.

Increased pigmentation within the bed

of the transplant.

Impact on Acuity

Recorded functional visual

improvements in both patients.

Preliminary Results

13

Persistence of cells

Anatomical evidence of hESC-RPE

survival and engraftment.

Increased pigmentation within the bed

of the transplant.

Engraftment and Survival: SD-OCT image collected at month 3

show survival and engraftment of RPE

Preliminary Results

14

Baseline

Injection site

Month 1 Month 2

Increased pigmentation within the bed

of the transplant.

Persistence of cells

Preliminary Results

15

• Varying degrees of improvement in visual acuity across

patients

Persistence for 18+ months in first patients • Increased letters on ETDRS Charts

• Color perception

• Contrast

• Low light vision

These are very late stage patients with a high degree of

heterogeneity in degree of “rescueable” photoreceptors

Impact on Visual Acuity

Halfway Point

16

Based on safety and functional data from first 18 patients,

FDA has approved new 4 patient cohorts in each trial.

Best Vision Inclusion Criteria for new Cohort 2a

includes patients with vision as good as 20/100.

50K Cells 100K Cells 150K Cells 200K Cells

100K Cells FDA Approved “Cohort 2a”

Inclusion Criteria: vision 20/100+

Current Safety Profile

17

14 SMD Patients Treated

6 patients (50K cells cohort) treated – US&UK Trials > Cohort Complete

6 patient (100K cells cohort) treated – US&UK Trials > Cohort Complete

1 patient (150K cells cohort) treated – US

1 patient (“Cohort 2a”) treated – US

7 dry AMD Patients Treated

3 patients (50K cells cohort) treated > Cohort Complete

3 patient (100K cells cohort) treated > Cohort Complete

1 patient (150K cells cohort) treated – US

RPE Program Milestone Objectives

18

Key upcoming milestones

• Continue to treat and review patient data

• Treat earlier stage disease to determine

curative power of dissociated cell injections

• Define efficacy endpoints and targeted

patient visual criteria

• Simplify shipping and cell-prep to enhance

scaled distribution platform

Expanding Clinical Programs

19

Myopia creates a higher risk of permanent vision loss due

to Myopic Macular Degeneration (MMD)

• Severe near-sightedness causes elongation of the eyeball --

which can cause fissures in RPE layer.

January 2013 - FDA Approved

MMD Phase I/II study Jules Stein Eye Institute (UCLA) and ACT

Intellectual Property – RPE Program

Dominant Patent Position for Treating Retinal Degeneration

Broad Coverage for Manufacturing RPE Cells

Broad protection of pharmaceutical preparations

• RPE cell suspensions

• scaffolded RPE layers.

RPE Cells derived from other pluripotent stem cells

Vigilant filing on improvements

20

Therapeutic Pipeline

21

Retinal Neural Progenitor cells

& Isolated Protective Factors Photoreceptor Loss, Modulation of Müller Cells

Protection of Retinal Ganglion cells (Glaucoma)

Corneal Endothelium Corneal Disease

Hemangioblast cells Ischemic retinopathy

– diabetic retinopathy, vascular occlusions

Mesenchymal Stromal Cells Ocular - Glaucoma, Uveitis, Retinitis Pigmentosa

Autoimmune Diseases

Inflammatory Diseases or disorders

Generation of Blood Products

22

Hemangioblasts RBCs Hemangioblasts Enucleated

RBC’s

Process generates large

quantities of functional

red blood cells

and

megakaryocytes &

platelets

ACT Corporate Overview

Financial Update – Strong Balance Sheet

24

• Company ended 2012 Q4 with $40 million in

cash or availability of cash through financing

commitments

• $16 million annual cash-burn rate

(funded through early 2015)

• Settled nearly all litigation hangover from

previous management

ACT Management Team

Highly Experienced and Tightly Integrated Management Team

Gary Rabin – Chairman & CEO

Dr. Robert Lanza, M.D. – Chief Scientific Officer

Edmund Mickunas – Vice President of Regulatory Affairs

Dr. Irina Klimanskaya, Ph.D. – Director of Stem Cell Biology

Dr. Shi-Jiang (John) Lu, Ph.D. – Senior Director of Research

Dr. Roger Gay, Ph.D. - Senior Director of Manufacturing

Kathy Singh - Controller

Rita Parker – Director of Operations

Dr. Matthew Vincent, Ph.D. – Director of Business Development

Bill Douglass – Dir. of Corporate Communications & Social Media

25

Dr. Ronald M. Green: Chairman

Dr. Judith Bernstein

Dr. Jeremy B.A. Green

Dr. Robert Kauffman

Dr. Carol A. Tauer

ACT Leadership

Gary Rabin: Chairman & CEO

Dr. Robert S. Langer, ScD: Prolific medical inventor; Chair – ACT SAB

Gregory S. Perry: EVP – Immunogen

Michael Heffernan: CEO – Collegium Pharma

Zohar Loshitzer: CEO Presbia; Founder LifeAlert Medical

Dr. Alan C. Shapiro: Renowned business school professor

26

World Class Board of Directors

Highly-regarded Ethics Advisory Board

Thank you

For more information, visit www.advancedcell.com